Abstracts tagged "gout and hyperuricemia"

Abstract Number: 1149 • 2018 ACR/ARHP Annual Meeting
Contemporary Prevalence of Gout and Hyperuricemia in the United States (National Health and Nutrition Examination Survey [NHANES] 2015-2016) and Decadal Trends (NHANES 2007-2016)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: The prevalences of gout and hyperuricemia from the National Health and Nutrition Examination Survey (NHANES) 2007-2008 were 3.9% (8.3 million) and 21.4% (43.3 million…
Abstract Number: 2236 • 2018 ACR/ARHP Annual Meeting
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Precise estimates of the comorbidity burden of gout and hyperuricemia are critical as their presence has important implications for the treatment of both gout…
Abstract Number: 1021 • 2017 ACR/ARHP Annual Meeting
GWAS of Gout in Patients with Hyperuricemia Identified Many Possible New Candidate Risk Alleles
Jing Cui¹, Zhi Zhang¹, Elizabeth Karlson² and Daniel H. Solomon², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Virtually all gout patients have high levels of uric acid in the blood (hyperurincemia, HU), but approximately 80% of patients with HU will never…
Abstract Number: 2069 • 2017 ACR/ARHP Annual Meeting
Gout Is More Frequent in Sickle Cell Disease Than the General Population
Richard Akintayo¹, Olufemi Adelowo², Adindu Chijioke¹, Timothy Olanrewaju¹, Kehinde Olufemi-Aworinde³ and Foluke Akintayo⁴, ¹Internal Medicine, University of Ilorin Teaching Hospital, Ilorin, Nigeria, ²Arthrimed Specialist Clinic:The Arthritis Centre, Lagos, Nigeria, ³Haematology, Bowen University Teaching Hospital, Ogbomosho, Nigeria, ⁴Family Medicine, Ladoke Akintola University of Technology Teaching Hospital, Ogbomosho, Nigeria
Background/Purpose: Despite the well known risk of hyperuricaemia in Sickle Cell Disease (SCD), it has not been determined if these patients are more prone to…
Abstract Number: 2088 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Urate Deposition in Tendon: A Dual-Energy CT Study
In Young Kim¹, Yeonghee Eun², Ji young Chai³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hyungjin Kim², Jaejoon Lee¹, Eun-Mi Koh² and Hoon-Suk Cha⁶, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Rheumatology, Bundang Jesaeng Hospital, Seongnam, Korea, Republic of (South), ⁴Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea, Republic of (South), ⁶Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Dual-energy computed tomography (DECT) is advanced imaging modality that shows the deposition of monosodium urate (MSU) crystal in tissue as a color signal. In…
Abstract Number: 2989 • 2017 ACR/ARHP Annual Meeting
Hydration and Gout: Looking at New Modes of Uric Acid Management
Patricia Kachur¹, Chirag Bambhroliya², Hong Liang³ and Pramil Cheriyath², ¹Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ²Ocala Regional Medical Center, Ocala, FL, ³North Florida Regional Medical Center, Gainsville, FL
Background/Purpose: Gout affects more than 4% of adults in the United States, and it is the most common form of inflammatory arthritis among men. Studies…
Abstract Number: 75 • 2016 ACR/ARHP Annual Meeting
Genetic Analysis of Urate Transporters ABCG2, SLC17A3, SLC22A11 and SLC17A1 in Primary Hyperuricemia and Gout
Blanka Stiburkova^1,2, Pavel Cepek¹, Lenka Petru^1,3, Katerina Pavelcova^1,3, Jakub Zavada⁴ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The urate transporters are one of the genetic determinants of serum uric acid concentrations. In the present study, we describe the analysis of sequencing…
Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
John FitzGerald¹, Benjamin D. Levine², Jennifer Raymond³ and Maureen A. McMahon¹, ¹Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…
Abstract Number: 752 • 2015 ACR/ARHP Annual Meeting
A Strong Association Between Gout and Diuretic Use Among Lupus Patients
Eric Wise¹, Emily Lewis², Puja Khanna^2,3, Lili Zhao⁴ and W Joseph McCune⁵, ¹Rhuematology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁴Department of Statistic, University of Michigan, Ann Arbor, MI, ⁵Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: Although gout has historically been thought to be a rare in patients with SLE, recent case series suggest that the incidence of gout in…
Abstract Number: 2964 • 2014 ACR/ARHP Annual Meeting
Association Analysis of Apolipoprotein B and Very Low-Density Lipoprotein with Hyperuricemia and Gout
Humaira Rasheed¹, Angela Hsu¹, Nicola Dalbeth², Lisa K. Stamp³, Sally McCormick¹ and Tony R. Merriman¹, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: Gout results from an innate immune response to monosodium urate (MSU) crystals deposited in joints. Increased very low-density lipoprotein (VLDL) has been associated with…
Abstract Number: 1136 • 2014 ACR/ARHP Annual Meeting
Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter
David B. Mount^1,2, Tony R. Merriman³, Eli A. Stahl⁴, Hyon K. Choi⁵ and Asim Mandal¹, ¹Renal Division, Brigham and Women's Hospital, Boston, MA, ²Renal Division, VA Boston Healthcare System, Boston, MA, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴Mt Sinai School of Medicine, New York City, NY, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Variation in SLC2A9, which encodes the urate transporter GLUT9, is the major single genetic determinant of serum uric acid (SUA); however, the causal variant(s)…
Abstract Number: 901 • 2014 ACR/ARHP Annual Meeting
Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target?
Robert Morlock¹, David M. Kern², Ozgur Tunceli², Siting Zhou², Laura Horne³, Sulabha Ramachandran³ and Hyon K. Choi⁴, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²HealthCore, Inc., Wilmington, DE, ³AstraZeneca, Wilmington, DE, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by chronic hyperuricemia, leading to urate crystal deposition disease and subsequent intermittent…
Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Seoyoung C. Kim¹, John D. Seeger², Jun Liu³ and Daniel H. Solomon⁴, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout
Seoyoung C. Kim¹, Sebastian Schneeweiss², Niteesh Choudhry³, Jun Liu⁴, Robert J. Glynn³ and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].